Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Hypogonadism and its treatment among prostate cancer survivors

Abstract

Adult-onset hypogonadism (AOH) is associated with sexual dysfunction, poor bone mineralization, decreased muscle mass, metabolic syndrome disorder, and cognitive suppression. Historically, testosterone has been contraindicated in men with a history of prostate cancer. However, there has been a modern resurgence in re-evaluating this belief. Not only can testosterone be safely utilized to alleviate AOH symptoms in prostate cancer survivors, it has been also touted as a treatment option for aggressive prostatic cancer. While much work remains in understanding the relationship between testosterone and prostate cancer, those who survive this disease should not be automatically turned away from an opportunity to be treated and restored.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol. 2000;161:73–88.

    CAS  PubMed  Google Scholar 

  2. 2.

    Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S, Punab M. EAU guidelines on male hypogonadism. Arnhem, The Netherlands: European Association of Urology; 2016.

  3. 3.

    Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society* clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1715–44.

    PubMed  Google Scholar 

  4. 4.

    Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am. 2007;36:333–48.

    CAS  PubMed  Google Scholar 

  5. 5.

    Muller M, Grobbee DE, den Tonkelaar I, Lamberts SWJ, van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab. 2005;90.2618–23.

    CAS  PubMed  Google Scholar 

  6. 6.

    Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843–50.

    CAS  PubMed  Google Scholar 

  7. 7.

    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724–31.

    CAS  PubMed  Google Scholar 

  8. 8.

    Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589–98.

    CAS  PubMed  Google Scholar 

  9. 9.

    Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the massachusetts male aging study. J Clin Endocrinol Metab. 2004;89:5920–6.

    CAS  PubMed  Google Scholar 

  10. 10.

    Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008;10:111–9.

    PubMed  PubMed Central  Google Scholar 

  11. 11.

    Khera M. Androgen replacement therapy after prostate cancer treatment. Curr Urol Rep. 2010;11:393–9.

    PubMed  Google Scholar 

  12. 12.

    Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol. 1998;160:2418–24.

    CAS  PubMed  Google Scholar 

  13. 13.

    Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer control Control 2008;19:175–81.

    Google Scholar 

  14. 14.

    Barry MJ, Simmons LH. Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med Clin North Am. 2017;101(Jul):787–806.

    PubMed  Google Scholar 

  15. 15.

    American Cancer Society. Key statistics for prostate cancer. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. American Cancer Society, Atlanta, 2018.

  16. 16.

    Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F. Testosterone therapy in men with prostate cancer. European urology. 2016;69:894–903.

  17. 17.

    Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. Eur J Endocrinol. 2008;159:507–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427–48.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310–20.

    PubMed  Google Scholar 

  20. 20.

    Bell MA, Campbell JD, Joice G, Sopko NA, Burnett AL. Shifting the paradigm of testosterone replacement therapy in prostate cancer. World J Mens Health. 2018;36:103–9.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Shea JL, Wong P-Y, Chen Y. Free testosterone. In: Advances in clinical chemistry. Elsevier; 2014. p. 59–84. https://linkinghub.elsevier.com/retrieve/pii/B9780128000946000029.

  22. 22.

    Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum testosterone levels in male hypogonadism: why and when to check-A review. Int J Clin Pr. 2017;71:e12995.

    Google Scholar 

  23. 23.

    Woodworth A, McCudden C. Laboratory testing in pregnancy and reproductive disorders. In: Contemporary practice in clinical chemistry. 2nd ed. Washington, DC: American Association for Clinical Chemistry, Inc; 2011. p. 471–93.

  24. 24.

    Swyer GI. Post-natal growth changes in the human prostate. J Anat. 1944;78:130–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Huggins C. The etiology of benign prostatic hypertrophy. Bull N. Y Acad Med. 1947;23:696–704.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172:1399–403.

    CAS  PubMed  Google Scholar 

  27. 27.

    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl J Med. 1999;341:1781–8.

    CAS  PubMed  Google Scholar 

  28. 28.

    Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet Lond Engl. 2002;360:103–6.

    CAS  Google Scholar 

  29. 29.

    Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N. Engl J Med. 2003;349:215–24.

    CAS  PubMed  Google Scholar 

  30. 30.

    Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.

    CAS  PubMed  Google Scholar 

  31. 31.

    Rove KO, Crawford ED. Traditional androgen ablation approaches to advanced prostate cancer: new insights. Can J Urol. 2014;21:14–21.

    PubMed  Google Scholar 

  32. 32.

    Rodriguez KM, Pastuszak AW, Khera M. The role of testosterone therapy in the setting of prostate cancer. Curr Urol Rep. 2018;19:67.

    PubMed  Google Scholar 

  33. 33.

    Yassin A, AlRumaihi K, Alzubaidi R, Alkadhi S, Al Ansari A. Testosterone, testosterone therapy and prostate cancer. Aging Male Off J Int Soc Study. Aging Male. 2019;22:219–27.

    CAS  PubMed  Google Scholar 

  34. 34.

    Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2:389–96.

    CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006;50:935–9.

    CAS  PubMed  Google Scholar 

  36. 36.

    Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83.

    PubMed Central  Google Scholar 

  37. 37.

    Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol. 2012;62:757–64.

    CAS  PubMed  Google Scholar 

  38. 38.

    Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68:1263–7.

    PubMed  Google Scholar 

  39. 39.

    García-Cruz E, Piqueras M, Ribal MJ, Huguet J, Serapiao R, Peri L, et al. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia: testosterone as predictor of PCA in patients with HGPIN. BJU Int. 2012;110:E199–202.

    PubMed  Google Scholar 

  40. 40.

    Risbridger GP, Ball EMA, Wang H, Mellor SL, Peehl DM. Re-evaluation of inhibin α subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol. 2004;225:73–6.

    CAS  PubMed  Google Scholar 

  41. 41.

    Porcaro AB, Monaco C, Romano M, Petrozziello A, Rubilotta E, Lacola V, et al. Investigative Clinical Study on Prostate Cancer Part II: on the role of the pretreatment total PSA to free testosterone ratio as a marker assessing prostate cancer prognostic groups after radical retropubic prostatectomy. Urol Int. 2010;85:152–8.

    CAS  PubMed  Google Scholar 

  42. 42.

    Neuzillet Y, Raynaud J-P, Dreyfus J-F, Radulescu C, Rouanne M, Schneider M, et al. Aggressiveness of localized prostate cancer: the key value of testosterone deficiency evaluated by both total and bioavailable testosterone: AndroCan Study Results. Horm Cancer. 2019;10:36–44.

    CAS  PubMed  Google Scholar 

  43. 43.

    Massengill JC, Sun L, Moul JW, Wu H, McLEOD DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670–5.

    PubMed  Google Scholar 

  44. 44.

    Salonia A, Gallina A, Briganti A, Abdollah F, Suardi N, Capitanio U, et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer. 2011;117:3953–62.

    PubMed  Google Scholar 

  45. 45.

    Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res. 2012;18:3648–57.

    CAS  PubMed  Google Scholar 

  46. 46.

    Monath JR, McCullough DL, Hart LJ, Jarow JP. Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology. 1995;46:58–61.

    CAS  PubMed  Google Scholar 

  47. 47.

    Mohr BA, Feldman HA, Kalish LA, Longcope C, McKinlay JB. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology. 2001;57:930–5.

    CAS  PubMed  Google Scholar 

  48. 48.

    Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281:E1172–1181.

    CAS  PubMed  Google Scholar 

  49. 49.

    Khera M, Miner M, Bhattacharya R, Blick G, Kushner H, Nguyen D. 1379 PSA levels significantly rise after 3 months of testosterone replacement therapy in severely hypogonadal men in the TESTIM Registry in the US (TRIUS) cohort. J Urol. 2010;183. https://doi.org/10.1016/j.juro.2010.02.1008.

  50. 50.

    Cooper CS, MacIndoe JH, Perry PJ, Yates WR, Williams RD. The effect of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol. 1996;156:438–41. discussion 441-442

    CAS  PubMed  Google Scholar 

  51. 51.

    Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pr J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2000;6:132–8.

    CAS  Google Scholar 

  52. 52.

    Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 2002;23:922–6.

    PubMed  Google Scholar 

  53. 53.

    Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl J Med. 1996;335:1–7.

    CAS  PubMed  Google Scholar 

  54. 54.

    Cooper CS, Perry PJ, Sparks AE, MacIndoe JH, Yates WR, Williams RD. Effect of exogenous testosterone on prostate volume, serum and semen prostate specific antigen levels in healthy young men. J Urol. 1998;159:441–3.

    CAS  PubMed  Google Scholar 

  55. 55.

    Emmelot-Vonk MH, Verhaar HJJ, Nakhai Pour HR, Aleman A. Lock TMTW, Bosch JLHR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39–52.

    CAS  PubMed  Google Scholar 

  56. 56.

    Nair KS, Rizza RA, O’Brien P, Dhatariya K, Short KR, Nehra A, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N. Engl J Med. 2006;355(Oct):1647–59.

    CAS  PubMed  Google Scholar 

  57. 57.

    Bhasin S, Bremner WJ. Clinical review 85: emerging issues in androgen replacement therapy. J Clin Endocrinol Metab. 1997;82:3–8.

    CAS  PubMed  Google Scholar 

  58. 58.

    Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl. 2010;31:457–65.

    CAS  PubMed  Google Scholar 

  59. 59.

    Xu P, Choi E, El-Khatib FM, Yafi FA. Post-market single center experience with a subcutaneous auto-injector of testosterone enanthate (Xyosted). Eur Urol Open Sci. 2020;19:e129.

    Google Scholar 

  60. 60.

    Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Inter Aging. 2009;4:397–412.

    CAS  Google Scholar 

  61. 61.

    Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32.

    PubMed  Google Scholar 

  62. 62.

    DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(Aug):252–71.

    Google Scholar 

  63. 63.

    Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. What do prostate cancer patients die of? Oncologist. 2011;16:175–81.

    PubMed  PubMed Central  Google Scholar 

  64. 64.

    Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, Ingelsson E, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. Lancet Oncol. 2010;11:450–8.

    PubMed  PubMed Central  Google Scholar 

  65. 65.

    Holzbeierlein JM, McLaughlin MD, Thrasher JB. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol. 2004;14:177–83.

    PubMed  Google Scholar 

  66. 66.

    Gay HA, Sanda MG, Liu J, Wu N, Hamstra DA, Wei JT, et al. External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: results of a multicenter, prospective study of quality of life. Int J Radiat Oncol Biol Phys. 2017;98:304–17.

    PubMed  PubMed Central  Google Scholar 

  67. 67.

    Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol. 2003;21:392–8.

    CAS  PubMed  Google Scholar 

  68. 68.

    Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N. Engl J Med. 2005;352:154–64.

    CAS  PubMed  Google Scholar 

  69. 69.

    Chang D, Joseph DJ, Ebert MA, Galvão DA, Taaffe DR, Denham JW, et al. Effect of androgen deprivation therapy on muscle attenuation in men with prostate cancer. J Med Imaging Radiat Oncol. 2014;58:223–8.

    PubMed  Google Scholar 

  70. 70.

    Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, et al. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011;107:924–8.

    PubMed  Google Scholar 

  71. 71.

    Braunstein LZ, Chen M-H, Loffredo M, Kantoff PW, D’Amico AV. Obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer. Prostate Cancer. 2014;2014:230812.

    PubMed  PubMed Central  Google Scholar 

  72. 72.

    Bosco C, Crawley D, Adolfsson J, Rudman S, Van, Hemelrijck M. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis. PloS One. 2015;10:e0117344.

    PubMed  PubMed Central  Google Scholar 

  73. 73.

    Mitsuzuka K, Kyan A, Sato T, Orikasa K, Miyazato M, Aoki H, et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis. 2016;19:57–62.

    CAS  PubMed  Google Scholar 

  74. 74.

    Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of the “androgen deprivation syndrome” in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465–71.

    PubMed  PubMed Central  Google Scholar 

  75. 75.

    Ehdaie B, Atoria CL, Gupta A, Feifer A, Lowrance WT, Morris MJ, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer. 2012;118:3397–406.

    CAS  PubMed  Google Scholar 

  76. 76.

    Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer. 2016 ;16:180.

    PubMed  PubMed Central  Google Scholar 

  77. 77.

    Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male J Int Soc Study Aging Male. 2002;5:98–102.

    CAS  Google Scholar 

  78. 78.

    Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt–a major factor in the genesis of morbid obesity. Med Hypotheses. 1999;52:49–51.

    CAS  PubMed  Google Scholar 

  79. 79.

    Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144:5081–8.

    CAS  PubMed  Google Scholar 

  80. 80.

    Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson K-F, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28:1636–42.

    CAS  PubMed  Google Scholar 

  81. 81.

    Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol. 2005;174:2178–80.

    CAS  PubMed  Google Scholar 

  82. 82.

    Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52:696–701.

    CAS  PubMed  Google Scholar 

  83. 83.

    Thompson IM, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl J Med. 2013;369:603–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. 84.

    Liu Z, Liu J, Shi X, Wang L, Yang Y, Tao M, et al. Comparing calculated free testosterone with total testosterone for screening and diagnosing late-onset hypogonadism in aged males: a cross-sectional study. J Clin Lab Anal. 2017;31:e22073.

  85. 85.

    Lenfant L, Leon P, Cancel-Tassin G, Audouin M, Staerman F, Rouprêt M, et al. Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer. Urol Oncol. 2020;38:661–70.

  86. 86.

    Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166:1660–5.

    CAS  PubMed  Google Scholar 

  87. 87.

    Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116:2694–701.

    CAS  PubMed  Google Scholar 

  88. 88.

    Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75.

    CAS  PubMed  Google Scholar 

  89. 89.

    Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003;26:1869–73.

    CAS  PubMed  Google Scholar 

  90. 90.

    Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8:272–83.

    CAS  PubMed  Google Scholar 

  91. 91.

    Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, et al. Effect of comorbidity on prostate cancer-specific mortality: a prospective observational study. J Clin Oncol J Am Soc Clin Oncol 2017;35:3566–74.

    Google Scholar 

  92. 92.

    Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, et al. Charlson Comorbidity Index Is an Important Prognostic Factor for Long-Term Survival Outcomes in Korean Men with Prostate Cancer after Radical Prostatectomy. Yonsei Med J. 2014;55:316.

    PubMed  PubMed Central  Google Scholar 

  93. 93.

    Park JW, Koh DH, Jang WS, Lee JY, Cho KS, Ham WS, et al. Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients. PloS One. 2018;13:e0199365.

    PubMed  PubMed Central  Google Scholar 

  94. 94.

    Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology 2010;76:553–7.

    PubMed  PubMed Central  Google Scholar 

  95. 95.

    Lin Y-T, Lee MT-S, Huang Y-C, Liu C-K, Li Y-T, Chen M. Prediction of recurrence-associated death from localized prostate cancer with a charlson comorbidity index-reinforced machine learning model. Open Med Wars Pol. 2019;14:593–606.

    Google Scholar 

  96. 96.

    Ghanem AI, Khalil RM, Khedr GA, Tang A, Elsaid AA, Chetty IJ, et al. Charlson Comorbidity score influence on prostate cancer survival and radiation-related toxicity. Can J Urol. 2020;27:10154–61.

    PubMed  Google Scholar 

  97. 97.

    Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–2.

    CAS  PubMed  Google Scholar 

  98. 98.

    Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–6.

    CAS  PubMed  Google Scholar 

  99. 99.

    Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. 100.

    Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–41.

    CAS  PubMed  Google Scholar 

  101. 101.

    Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25:24–8.

    CAS  PubMed  Google Scholar 

  102. 102.

    Balbontin FG, Moreno SA, Bley E, Chacon R, Silva A, Morgentaler A. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer: Testosterone therapy for treating testosterone deficiency after brachytherapy. BJU Int. 2014;114:125–30.

    CAS  PubMed  Google Scholar 

  103. 103.

    Kaplan AL, Trinh Q, Sun M, Carter SC, Nguyen PL, Shih YT, et al. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends. J Sex Med. 2014;11:1063–70.

    CAS  PubMed  Google Scholar 

  104. 104.

    Kardoust Parizi M, Abufaraj M, Fajkovic H, Kimura S, Iwata T, D’Andrea D, et al. Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol. 2019;37:637–46.

    CAS  PubMed  Google Scholar 

  105. 105.

    Pisansky TM, Thompson IM, Valicenti RK, D’Amico AV, Selvarajah S. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline amendment 2018-2019. J Urol. 2019;202:533–8.

    PubMed  Google Scholar 

  106. 106.

    Hatzoglou A, Kampa M, Kogia C, Charalampopoulos I, Theodoropoulos PA, Anezinis P, et al. Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo. J Clin Endocrinol Metab. 2005;90:893–903.

    CAS  PubMed  Google Scholar 

  107. 107.

    Yassin A, Salman M, Talib RA, Yassin D-J. Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register. Aging Male J Int Soc Study Aging Male. 2017;20:125–33.

    CAS  Google Scholar 

  108. 108.

    Ahlering TE, My Huynh L, Towe M, See K, Tran J, Osann K, et al. Testosterone replacement therapy reduces biochemical recurrence after radical prostatectomy. BJU Int. 2020;126:91–6.

  109. 109.

    Krakowsky Y, Morgentaler A. 132 initial experience with testosterone therapy in selected men with advanced or metastatic prostate cancer. J Sex Med. 2018;15:S33–4.

  110. 110.

    Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010;70:1600–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  111. 111.

    Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2.

    PubMed  PubMed Central  Google Scholar 

  112. 112.

    Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA. 1996;93:11802–7.

    CAS  PubMed  Google Scholar 

  113. 113.

    Sedelaar JPM, Isaacs JT. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate. 2009;69:1724–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  114. 114.

    Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, et al. Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: results from the phase II BATMAN study: high-dose testosterone in hormone-sensitive prostate cancer. Prostate. 2016;76:1218–26.

    CAS  PubMed  Google Scholar 

  115. 115.

    Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, et al. Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol. 2018;19:76–86.

    CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Faysal A. Yafi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Choi, E.J., Xu, P., el-Khatib, F.M. et al. Hypogonadism and its treatment among prostate cancer survivors. Int J Impot Res 33, 480–487 (2021). https://doi.org/10.1038/s41443-020-00387-3

Download citation

Further reading

Search

Quick links